ASTEC LIFESCIENCES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,410 INR | -1.38% |
|
+0.67% | +28.78% |
| Jun. 14 | India Ratings Keeps AA- Rating on Astec Lifesciences' Bonds; Outlook Stable | MT |
| May. 03 | Astec Lifesciences' CFO Resigns | MT |
Valuation
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,598 | 19,653 | 34,391 | 27,154 | 20,932 | 28,040 | - |
| Enterprise Value (EV) 1 | 7,598 | 21,507 | 37,163 | 27,154 | 20,932 | 28,040 | 28,040 |
| P/E ratio | 16 x | 30.2 x | 38.3 x | 106 x | -44.6 x | 48.5 x | 30.1 x |
| Yield | - | 0.15% | 0.09% | 0.11% | - | 0.07% | 0.07% |
| Capitalization / Revenue | 1.45 x | 3.54 x | 5.08 x | 4.32 x | 4.57 x | 4.15 x | 3.22 x |
| EV / Revenue | 1.45 x | 3.54 x | 5.08 x | 4.32 x | 4.57 x | 4.15 x | 3.22 x |
| EV / EBITDA | - | 17.6 x | 22.3 x | 35.6 x | -354 x | 20.6 x | 14.1 x |
| EV / FCF | - | -17,754,754 x | -42,788,249 x | - | - | - | - |
| FCF Yield | - | -0% | -0% | - | - | - | - |
| Price to Book | - | 6.36 x | 8.68 x | - | 5.67 x | 6.47 x | 5.34 x |
| Nbr of stocks (in thousands) | 19,568 | 19,578 | 19,593 | 19,606 | 19,609 | 19,610 | - |
| Reference price 2 | 388.3 | 1,004 | 1,755 | 1,385 | 1,067 | 1,430 | 1,430 |
| Announcement Date | 5/5/20 | 4/30/21 | 5/2/22 | 5/2/23 | 5/2/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,226 | 5,549 | 6,766 | 6,282 | 4,582 | 6,756 | 8,716 |
| EBITDA 1 | - | 1,116 | 1,541 | 762.5 | -59.13 | 1,359 | 1,985 |
| EBIT 1 | - | 859 | 1,197 | 426 | -421.7 | 888 | 1,420 |
| Operating Margin | - | 15.48% | 17.69% | 6.78% | -9.2% | 13.14% | 16.29% |
| Earnings before Tax (EBT) 1 | - | 890.7 | 1,211 | 349.5 | -617.5 | 733 | 1,244 |
| Net income 1 | - | 650.5 | 898.6 | 255.6 | -469.3 | 579 | 931 |
| Net margin | - | 11.72% | 13.28% | 4.07% | -10.24% | 8.57% | 10.68% |
| EPS 2 | 24.27 | 33.21 | 45.85 | 13.04 | -23.93 | 29.50 | 47.50 |
| Free Cash Flow | - | -1,107 | -803.7 | - | - | - | - |
| FCF margin | - | -19.95% | -11.88% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 1.500 | 1.500 | 1.500 | - | 1.000 | 1.000 |
| Announcement Date | 5/5/20 | 4/30/21 | 5/2/22 | 5/2/23 | 5/2/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,734 | 2,720 | 1,843 | 1,997 | 1,172 | 1,270 | 1,428 | 1,108 | 507.9 | 1,537 | - |
| EBITDA 1 | 428.6 | 654.6 | 254.5 | 332.8 | 121.2 | 54 | 31.32 | -34.23 | -183.3 | 127.1 | -56.22 |
| EBIT 1 | - | - | - | - | - | - | -62.53 | - | -252.2 | 37.02 | - |
| Operating Margin | - | - | - | - | - | - | -4.38% | - | -49.64% | 2.41% | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | - | 430.5 | - | - | - | - | -81.95 | - | - | -9.739 | - |
| Net margin | - | 15.83% | - | - | - | - | -5.74% | - | - | -0.63% | - |
| EPS 2 | 12.62 | - | - | - | - | - | -4.180 | - | - | -0.5000 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 1/25/22 | 5/2/22 | 7/25/22 | 10/28/22 | 1/30/23 | 5/2/23 | 7/28/23 | 10/27/23 | 1/25/24 | 5/2/24 | 5/2/24 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | 1,855 | 2,772 | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 1.662 x | 1.799 x | - | - | - | - |
| Free Cash Flow | - | -1,107 | -804 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 23.4% | 25.5% | - | -11.9% | 14% | - |
| ROA (Net income/ Total Assets) | - | 10.4% | 11.4% | 2.73% | -11.9% | - | - |
| Assets 1 | - | 6,247 | 7,872 | 9,381 | 3,943 | - | - |
| Book Value Per Share 2 | - | 158.0 | 202.0 | - | 188.0 | 221.0 | 268.0 |
| Cash Flow per Share | - | -4.170 | - | - | - | - | - |
| Capex 1 | - | 1,025 | 1,040 | 1,173 | 1,355 | 1,200 | 1,200 |
| Capex / Sales | - | 18.48% | 15.37% | 18.67% | 29.57% | 17.76% | 13.77% |
| Announcement Date | 5/5/20 | 4/30/21 | 5/2/22 | 5/2/23 | 5/2/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1,430
INR
Average target price
1,108
INR
Spread / Average Target
-22.54%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +28.78% | 336M | |
| +7.93% | 36.05B | |
| -.--% | 11.72B | |
| +36.38% | 8.61B | |
| +10.21% | 6.83B | |
| -10.82% | 7.02B | |
| -11.83% | 5.63B | |
| -11.70% | 5.29B | |
| -3.32% | 5.11B | |
| +23.59% | 4.87B |
- Stock Market
- Equities
- ASTEC Stock
- Financials Astec LifeSciences Limited
